
Emestedastat for Alzheimer Disease Falls Short Overall, Signals Subgroup Benefit
Key Takeaways
- Topline efficacy did not separate from placebo on CDR-SB across weeks 12, 24, and 36, limiting interpretability for disease-modifying claims in the biomarker-enriched population.
- Prespecified participants older than 75 years showed a higher zero-progression rate (40% vs 22%), yet mean CDR-SB difference remained nonsignificant, creating discordant efficacy signals.
Emestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.
Emestedastat (Xanamem), an investigational oral inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), did not meet its primary endpoint in the phase 2b/3 XanaMIA trial in mild to moderate Alzheimer disease, according to topline results from Actinogen Medical. In the overall population, the mean difference vs placebo on the Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB) at week 36 was 0.10 points (P = 0.65).¹ In a prespecified analysis of participants older than the median age of 75 years, the rate of zero CDR-SB progression was 40% with emestedastat vs 22% with placebo (P = 0.02).¹
XanaMIA was a randomized (1:1), double-blind, placebo-controlled trial of emestedastat 10 mg vs placebo over 36 weeks in 247 participants across Australia and the United States. Participants had mild to moderate Alzheimer disease and elevated levels of the blood biomarker pTau181. The primary endpoint was the placebo-subtracted difference in CDR-SB at weeks 12, 24, and 36. Key secondary endpoints were a cognition composite and a measure of activities of daily living.¹
In the overall population, emestedastat was numerically but not statistically superior to placebo on the primary endpoint, and small, nonsignificant trends favored the drug on both secondary endpoints.¹ In participants older than 75 years, the mean CDR-SB difference at week 36 was 0.39 points (P = 0.22), which the company described as 30% disease slowing and as similar to rates claimed by Eli Lilly and Eisai for donanemab and lecanemab.¹ No serious adverse events were attributed to the drug over 36 weeks, which the company said replicated the favorable safety profile previously established over up to 12 weeks of daily 10 mg dosing.¹
For prescribers, the signal is narrow and unconfirmed. The trial missed its primary endpoint, and the overall difference was small. The older-subgroup result is hypothesis-generating: the zero-progression comparison reached P = 0.02, but the continuous CDR-SB difference in the same group did not reach significance (P = 0.22), so the 2 measures were not fully concordant. The release did not report subgroup sizes, confidence intervals, or adjustment for multiple comparisons. The population is clinically relevant, since older patients often have polypharmacy, including acetylcholinesterase inhibitors, and the company noted a lack of drug-drug interaction potential.¹ Whether the age-related effect is real, and whether it extends to patients without elevated pTau181, remains unproven.
Emestedastat is a first-in-class, once-daily oral inhibitor of 11β-HSD1, a tissue cortisol synthesis enzyme, designed to lower cortisol in the hippocampus, gray matter, liver, and adipose tissue without blocking adrenal cortisol production.¹ The company cited chronically elevated cortisol as associated with Alzheimer disease progression and proposed that increased enzyme expression with age may explain the older-subgroup finding.¹ Emestedastat has been studied in 8 trials with more than 500 participants, including in depression, and is not approved by the US Food and Drug Administration or any other regulatory authority.
Actinogen plans further analyses and will present additional results at a future scientific meeting, and an open-label extension is ongoing.¹
References
1. Actinogen pivotal Alzheimer’s disease trial demonstrates clinical benefit in older patients with mild to moderate disease, favorable safety profile and trends towards benefit in the overall population. Press release. November 19, 2026. Accessed November 20, 2026.
2. Rolan P, Taylor J, Seckl J, et al. Development of Xanamem, an isoform 1 specific inhibitor of 11-βHSD, as a procognitive and disease modifying treatment for mild/moderate Alzheimer’s disease. A pharmacodynamic and biomarker driven approach. Alzheimers Dement. 2025;20(suppl 6):e089127. doi:10.1002/alz.089127
Related to this article








